Loading...
Loading...
AYLA| Name | Value |
|---|---|
| Revenues | 105.0K |
| Cost of Revenue | 143.0K |
| Gross Profit | -38.0K |
| Operating Expense | 9,728.0K |
| Operating I/L | -17,582.0K |
| Other Income/Expense | 8,069.0K |
| Interest Income | 0.0K |
| Pretax | -9,513.0K |
| Income Tax Expense | 75.0K |
| Net Income/Loss | -9,588.0K |
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company specializing in developing and commercializing small molecule therapeutics for rare and aggressive cancers. Their lead product candidate, AL101, is a potent, selective, injectable small molecule gamma secretase inhibitor (GSI) in Phase II clinical trial for recurrent/metastatic adenoid cystic carcinoma with Notch-activating mutations. Additionally, the company is developing AL102, an oral small molecule GSI in Phase II/III pivotal study for desmoid tumors, and has a collaboration with Novartis to develop AL102 for multiple myeloma treatment.
